Syquant Capital Sas Intra Cellular Therapies, Inc. Transaction History
Syquant Capital Sas
- $141 Million
- Q1 2025
A detailed history of Syquant Capital Sas transactions in Intra Cellular Therapies, Inc. stock. As of the latest transaction made, Syquant Capital Sas holds 266,228 shares of ITCI stock, worth $35.1 Million. This represents 24.92% of its overall portfolio holdings.
Number of Shares
266,228Holding current value
$35.1 Million% of portfolio
24.92%Shares
1 transactions
Others Institutions Holding ITCI
# of Institutions
413Shares Held
86.6MCall Options Held
284KPut Options Held
105K-
Vanguard Group Inc Valley Forge, PA9.72MShares$1.28 Billion0.01% of portfolio
-
Black Rock Inc. New York, NY6.32MShares$834 Million0.01% of portfolio
-
Jpmorgan Chase & CO New York, NY5.13MShares$676 Million0.03% of portfolio
-
Wasatch Advisors Inc Salt Lake City, UT3.25MShares$428 Million1.36% of portfolio
-
Norges Bank Oslo, Q83.21MShares$424 Million0.04% of portfolio
About Intra-Cellular Therapies, Inc.
- Ticker ITCI
- Exchange NASDAQ
- Sector Healthcare
- Industry Drug Manufacturers—Specialty & Generic
- Shares Outstandng 94,401,696
- Market Cap $12.4B
- Description
- Intra-Cellular Therapies, Inc., a biopharmaceutical company, develops novel drugs for the treatment of neuropsychiatric and neurologic diseases by targeting intracellular signaling mechanisms within the central nervous system in the United States. The company offers CAPLYTA for the treatment of schizophrenia in adults. It is also involved in dev...